Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 5,994
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
LYDIA  KISEKKA NAMATEEFU
ID: UNCST-2022-R011079
 APPRAISING THE RELATIONSHIP BETWEEN THE LAW ON LAND REGISTRATION IN UGANDA AND LAND GRABBING: A CASE STUDY OF KAYUNGA DISTRICT
REFNo: SS1204ES

To appraise the relationship between the law on land registration and the phenomenon of land grabbing in Uganda.

Specific Objectives
i. To conceptualize the law on land registration and the practice of land grabbing in Uganda with a specific focus on Kayunga District.
ii. To identify the nature and causes of land grabbing in Kayunga District.
iii. To conceptualize the impact of land grabbing on the economy of Uganda using Kayunga District as a case study.

Uganda 2022-07-26 9:53:21 2025-07-26 Social Science and Humanities Non-Clinical Trial Degree Award
Atupele Mlangwa Subira
ID:
PREVALENCE AND FACTORS ASSOCIATED WITH PROLONGED HOSPITAL STAY FOLLOWING CAESEREAN DELIVERY AT MBARARA REGIONAL REFERRAL HOSPITAL
REFNo: NS383ES

2. To determine the factors associated with prolonged hospital stay following caesarean delivery at MRRH,1. To determine the prevalence of prolonged hospital, stay following caesarean delivery at MRRH,To determine the prevalence and factors associated with prolonged hospital stay following caesarean delivery at MRRH,
 Tanzania 2022-07-26 11:29:37 2025-07-26 Natural Sciences Clinical Trial Degree Award
Barbara Alungat
ID:
THE URBAN POLICING PARADOX IN UGANDA: A CASE OF KAMPALA CITY
REFNo: SS1365ES

To explore the current responses by the police in enhancing urban peace enforcement in Kampala city.,To analyse the challenges of urban policing and peace enforcement in Kampala city. ,To examine the role of the Police in urban policing and peace enforcement in Kampala city. ,To explore the crimes accompanying rapid urbanisation in Kampala city,To examine the paradox of urban policing in Uganda with specific regard to how rapid urbanisation poses challenges for policing and urban peace enforcement in Kampala city even in the face of expansion and adequate tooling and equipping of the UPF.,
 Uganda 2022-07-26 10:07:57 2025-07-26 Social Science and Humanities Non-Clinical Trial Degree Award
Stella Muyanja Zawedde
ID: UNCST-2021-R014037
 Knowledge, attitudes and practices regarding Tuberculosis among communities in the Karamoja sub region, North Eastern Uganda.
REFNo: HS2342ES

Overall Objective
To establish knowledge, attitudes and practices of communities in the Karamoja sub region towards Tuberculosis prevention, diagnosis and treatment.

Specific Objective 1: To determine factors associated with correct knowledge about TB prevention, diagnosis and treatment.

Specific Objective 2: To understand patterns of behavior associated with TB prevention, diagnosis and treatment in the Karamoja subregion


 Uganda 2022-07-26 10:04:18 2025-07-26 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Schola  Matovu Nakachwa
ID: UNCST-2022-R011040
 Development of an Intervention Designed to Promote Economic Empowerment, Social Support, and Health of Grandmothers who Provide Primary Care for Grandchildren in Uganda.
REFNo: SS1376ES

To pilot a small intervention as informed by the refined intervention to test its acceptability and feasibility among Ugandan grandmother-caregivers 50 years and older (N=15).,To develop and refine the intervention components based on information gathered in objective 1 and through an iterative feedback process from the CAB. ,To use a formative community-engaged research approach to inform the development of a multicomponent intervention for grandmother-caregivers.,To use a formative community-engaged research approach to inform the development of an intervention that will promote economic empowerment, peer group support, and health education geared towards improving the quality of life andthe mental and physical health of grandmothers who provide primary care for grandchildren affected by HIV/AIDS and poverty in Uganda. ,
 USA 2022-07-25 12:36:36 2025-07-25 Social Science and Humanities Non-Clinical Trial Non-degree Award
Waiswa Peter
ID: UNCST-2020-R014921
 An assessment of Multiple COVID-19 vaccine roll out in Uganda: exploring barriers and facilitators to inform better program design
REFNo: HS2101ES

(4) Explore COVID-19 roll out and its effect on the implementation of routine vaccination.,(3) Assess the uptake and perceived hindrances to the issuance of the multiple vaccines in the country ,(2) Examine the availability and preparedness of the health workers to rolling out the multiple vaccines in the study districts ,(1) Explore the process of issuance, adherence to guidelines and the facilitators to the multiple COVID-19 vaccine roll out in Uganda ,To understand the roll-out process of multiple COVID-19 vaccines in the country, its barriers and facilitators. ,
 Uganda 2022-07-25 12:34:15 2025-07-25 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Frank NAMUGERA
ID:
Adoption and sustained use of efficient energy-saving technology (firewood cooking stoves) in Rwampara district, rural western Uganda.
REFNo: SS1346ES

To assess the impact of the adoption of improved cookstoves in communities near Bugamba forest, Rwampara District in western Uganda. Specific objectives: 1. To assess the knowledge, attitudes and practices of households towards energy consumption and quality of life in areas around Bugamba forest. 2. To assess the behavioral change patterns of individuals following the construction of the improved cookstoves. 3. To assess the changes in the quality of life of the communities after the adoption of the ICS. 4. To ascertain the impact of the adoption of clean energy cooking on the environment in the communities near Bugamba forest.
 Uganda 2022-07-25 11:14:17 2025-07-25 Social Science and Humanities Non-Clinical Trial Non-degree Award
PRISCILLA KASEMBO
ID:
REPORTED ADVERSE DRUG REACTIONS OF ANTIRETROVIRAL THERAPY GENERIC FORMULATIONS IN UGANDA
REFNo: HS2042ES

1.To assess the reported adverse drug reactions of the first line ART generic formulations containing Tenofovir, Lamivudine and Efavirenz or Dolutegravir (TDF/3TC/EFV or DTG)in Uganda.

2.To document the reported ADRs of the first line ART generic formulations containing TDF/3TC/EFV or DTG at National Pharmacovigilance Center, Kisenyi HC4, Kiswa HC 3 and Mildmay hospital in Uganda
3.To compare ADR profiles by severity between different ART generic formulations containing TDF/3TC/EFV or DTG.
4. To compare the ADR profile between the two first line ART regimens (DTG and EFV based generic formulations).
5. To explore ADR reporting among health workers at Kisenyi HC4, Kiswa HC 3 and Mildmay hospital in Uganda, in reference to particular first line ART generic formulations (TDF/3TC/EFV or DTG).


 Uganda 2022-07-22 15:00:41 2025-07-22 Medical and Health Sciences Non-Clinical Trial Degree Award
Winny Akullo Nekesa
ID:
Adoption of Linked Data among University libraries in Uganda
REFNo: SS1338ES

The study will address the following specific objectives:
1. Determine the level of awareness of Linked Data among the professional librarians in Ugandan Universities.
2. Establish the extent of Linked Data adoption in Ugandan Universities.
3. Determine the potential benefits of adopting Linked Data in Ugandan Universities.
4. Investigate the factors that influence the professional librarians’ behaviour towards the adoption of Linked Data in Ugandan Universities.
5. Investigate the strategies to promote the adoption of Linked Data in Ugandan Universities.

 Uganda 2022-07-21 11:01:06 2025-07-21 Social Science and Humanities Non-Clinical Trial Degree Award
Nixon Niyonzima
ID: UNCST-2020-R014577
 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY
REFNo: HS2173ES

8. To validate the ability of fertility biomarkers to diagnose and predict permanent loss of ovarian function, and to determine the impact of anti-cancer therapy on hormone levels,7. To evaluate health status utility scores of patients treated with atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine,6. To identify and/or evaluate biomarkers that are predictive of response to atezolizumab and trastuzumab emtansine (i.e., predictive biomarkers), are early surrogates of efficacy, are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with acquired resistance to atezolizumab and trastuzumab emtansine, are associated with susceptibility to developing adverse events or can lead to improved adverse event monitoring or investigation (i.e., safety biomarkers), can provide evidence of atezolizumab and trastuzumab emtansine activity (i.e., pharmacodynamic biomarkers), or can increase the knowledge and understanding of disease biology and drug safety,5. To evaluate the immune response to atezolizumab and trastuzumab emtansine,4. To characterize the PK profiles of atezolizumab and trastuzumab emtansine when given in combination,3. To evaluate the safety of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine,2. To evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in the PRO-evaluable analysis set,1. The secondary efficacy objective for this study is to evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in both the ITT population and PD-L1-positive population,The primary objective for this study is to evaluate the efficacy of atezolizumab when given in combination with trastuzumab emtansine compared with placebo and trastuzumab emtansine in both the ITT population (all comers) and the PD-L1-positive population (defined as all patients from the ITT population with a centrally assessed PD-L1-positive status [i.e., PD-L1 status of IC1/2/3] at randomization),
 Uganda 2022-07-21 11:00:02 2025-07-21 Medical and Health Sciences Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS